This invention relates to a
galantamine analogue with
cholinesterase-inhibiting activity, its preparation method, and its application. The general
structural formula is shown in formula (IA), (IB), or (IC). In formula (IA), R1 is selected from
hydrogen, o-
fluorine, m-
fluorine, p-
fluorine, 2,4-difluoro, m-
trifluoromethyl, p-methyl, 3,5-dimethoxy, p-chloro, p-nitro, p-cyano, or p-trifluoromethoxy. In formula (IB), R2 is selected from phenyl, o-fluorophenyl, m-fluorophenyl, p-fluorophenyl, 2,4-difluorophenyl, 3,5-difluorophenyl, o-methylphenyl, p-methylphenyl, p-methoxyphenyl, indole, p-cyanophenyl, p-trifluoromethylphenyl, p-trifluoromethoxyphenyl, p-nitrophenyl, or a
naphthalene ring. In formula (IC), R3 is selected from
hydrogen, o-fluorine, m-fluorine, p-fluorine, m-chloro, p-chloro, p-methyl, o-methoxy, m-methoxy, or p-methoxy. The
galantamine analogue of this invention exhibits superior inhibitory activity against
cholinesterase compared to
galantamine, and holds promise for the treatment of
cholinergic dysfunction-related diseases.